Latin America

GX Group has announced its entry into Latin America through a strategic partnership with Calculus Networks, marking a significant milestone in its global expansion strategy. The collaboration aims to broaden GX Group’s technological footprint while strengthening its ability to deliver advanced digital solutions across emerging markets. As Latin America accelerates its adoption of next-generation connectivity and enterprise technologies, the alliance positions both companies to capitalize on growing demand.

In a decisive move to expand its global footprint, Novac Technology has entered the Latin American market, marking a pivotal step in its international growth strategy. Known for its cutting-edge digital solutions and robust enterprise platforms, the company is setting its sights on emerging economies that promise strong demand for technology-driven transformation. This strategic foray underscores Novac’s ambition to capitalize on the region’s digital acceleration and growing appetite for IT services, as it seeks to deepen client engagement beyond its core markets.

The global health community is sounding the alarm after newly released data revealed that approximately 14 million children worldwide did not receive a single dose of routine vaccine in 2024. This troubling trend, described by experts as a “silent emergency,” poses a serious threat to hard-won progress against preventable diseases such as measles, polio, diphtheria, and tetanus. The majority of these children reside in low-income and conflict-affected regions, where fragile health systems and inequality continue to obstruct access to basic healthcare.

Pharmaceutical major Lupin Ltd. has entered into a strategic license and supply agreement with Costa Rica-based SteinCares to commercialize its biosimilar ranibizumab in Latin America, excluding Mexico and Argentina. Under this collaboration, SteinCares will lead regulatory filings and distribution, while Lupin will retain responsibility for manufacturing. The move aligns with Lupin’s broader vision of increasing access to advanced biologic therapies in emerging markets.